Source:http://linkedlifedata.com/resource/pubmed/id/10796687
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2000-7-6
|
pubmed:abstractText |
Systemic fungal infection is considered to be an important cause of morbidity and mortality in cancer patients, particularly those with neutropenia. Antifungal drugs are often given prophylactically, or to patients with persistent fever.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
1469-493X
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
CD000026
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading | |
pubmed:year |
2000
|
pubmed:articleTitle |
Routine versus selective antifungal administration for control of fungal infections in patients with cancer.
|
pubmed:affiliation |
The Nordic Cochrane Centre, Rigshospitalet, Blegdamsvej 9, Copenhagen O, Denmark, 2100. p.c.gotzsche@cochrane.dk
|
pubmed:publicationType |
Journal Article,
Review
|